Roche’s 22% Weight Loss Benefit Seals GLP-1’s Phase III Plans, Boosts Zealand Combo
Roche said the Phase II results help build the case for advancing CT-388 into late-stage testing, which is set to get underway this quarter.
Menopause Hormone Therapy May Boost GLP-1 Drug Benefits
(MedPage Today) — Postmenopausal women on the GLP-1 medication tirzepatide (Zepbound) for obesity lost more weight if they were also using menopause hormone therapy, a retrospective cohort study indicated.
Among 120 women with overweight or obesity…
The 5 Worst Things You Can Do While Taking a GLP-1 for Weight Loss
According to doctors, making a misstep is easier than you may think.
Genentech Announces Positive Phase II Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People Living With Obesity
South San Francisco, CA — January 26, 2026 — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from CT388-103, a Phase II clinical trial of CT-388, an investigational dual GLP-1/GIP…
Why I’m Choosing Not to Take GLP-1s, Even Though Everyone Expects Me To
I’m a candidate for the meds, but they’re not for me—at least for now.
Big Pharma shops Chinese biotechs to stock GLP-1 pipelines
Novo, Regeneron and Pfizer all landed weight loss deals with China-based companies last year.
Hormone therapy combined with tirzepatide linked to greater weight loss after menopause
A new study led by Mayo Clinic found that postmenopausal women receiving menopausal hormone therapy lost 35% more weight while taking tirzepatide, a Food and Drug Administration-approved drug for the treatment of overweight and obesity. The findings, published in The Lancet Obstetrics, Gynaecology, & Women’s Health, could expand treatment possibilities for millions of women struggling with obesity and obesity-related diseases after menopause.
GLP-1 medications: A comprehensive overview
With more studies emerging, GLP-1 and dual GIP/GLP-1 medications have become well-established options for those with obesity or type 2 diabetes.
Food Companies Are Targeting Users of Weight-Loss Drugs With ‘GLP-1 Friendly’ Labels
(MedPage Today) — Meals and snacks with “GLP-1 Friendly” labels on the packaging are becoming more common in U.S. supermarkets as a growing number of Americans try obesity drugs like semaglutide (Wegovy) and tirzepatide (Zepbound) to lose weight…
Summary of JP Morgan Conference in Obesity and Metabolic Diseases
Here’s a summary of the major announcements and trends from the 44th Annual JP Morgan Healthcare Conference in San Francisco (January 12–15, 2026) specifically in the areas of obesity, weight-loss drugs, metabolic disease, and adjacent therapies: (BioSpace) Fierce Biotechscanx.tradeReutersReutersAd Hoc News 🧠 1. Shift Toward Oral Obesity DrugsA major theme at JPM 2026 was the […]